Volume 35
Issue 2, 2015
ISSX President’s Message By John O. Miners, ISSX President I have just returned from the 13th European ISSX Meeting in Glasgow, which was attended by approximately 400 registrants. The organization of high-quality scientific meetings is a core activity of ISSX and I am happy to report that the Glasgow meeting met all expectations. The meeting co-chairs, Ann Daly and Roland Wolf, along with their colleagues on the Meeting Organizing Committee are to be congratulated for delivering an outstanding scientific program. ISSX promotes scientific excellence in the study of xenobiotic disposition and in this regard I also wish to congratulate Professor Brian Houston and Dr. Daniel Antoine, the respective recipients of the European Scientific Achievement Award and the European New Investigator Award (in honor of Professor Karl J. Netter). Brian and Daniel received their awards in Glasgow and delivered lectures during the course of the meeting. We now turn our attention to the 20th North American ISSX Meeting, which will be held in Orlando from October 18–22. Registration is now open and I urge
members to submit an abstract and contribute to the success of the meeting. Visit www.issx.org/20na for more information. The theme of this message is the organizational structure of ISSX— perhaps not exciting, but crucial to the existence of the Society. According to the ISSX bylaws, Council is responsible for facilitating the overall organization, administration, and communication of the Society, and the pursuit of its objectives on a worldwide basis. In fulfilling its remit, Council receives support from the ISSX Office in Washington, DC and from a number of committees. Current ISSX committees include the Awards, Finance, Nomination, Membership Affairs, and Scientific Affairs Committees, and the Committee on Regulatory Affairs. Council recently completed a review of the duties of the ISSX committees and these have been amended to reflect current practice and to facilitate the strategic objectives of ISSX. Committee duties are provided on the ISSX website
(www.issx.org/ committees). If you take the time to view these, you will appreciate the importance of the role that committees play in the running of the Society. The changes made to the committee duties have necessitated an update of the ISSX bylaws. Approval of the updated bylaws requires majority support of the ISSX membership. Members have received a message from the ISSX Office requesting your approval of the changes. Please take the time to respond. As I have indicated in previous messages, ISSX is dependent on the goodwill of its members for its activities, and this includes the functioning of committees. With the exception of the Nomination Committee, whose membership Continued on page 6
IN THIS ISSUE 1 2
ISSX President’s Message
3
Book Review: Principles
of Toxicology
4
7th International Symposium on Drug Metabolism and Pharmacokinetics Welcome New Members
7 20th North American Meeting 10 13th European ISSX Meeting in Review
Book Review PRINCIPLES OF TOXICOLOGY (3rd Edition) Authors: K.E. Stine, T.M. Brown CRC Press 455 pp., ISBN-13: 978-1-46650-342-4, 2015 The first line of the first chapter reads, “Toxicology is the science of poisons and has as its focus the study of the adverse effects of chemicals on living organisms” and this sets the scene for the entire text. Following a general introduction, the book details the journey of a xenobiotic through the body indicating what may happen to it en route with regards to chemical alteration. There then follows a section explaining the potential cellular sites of interaction before presenting the standard organ/system based approach to toxicity. The final six chapters discuss the application of toxicity testing and the use of this gained knowledge to various aspects such as forensics, food safety, and the ecosystem. As one would expect, many of the favorite “toxic” episodes and problems are mentioned including: persistent acid rain; algal bloom events; the cheese reaction; daffodil itch (lily rash); St. Anthony’s fire (in this case ergotism not infection-caused erysipelas); the Exxon Valdez oil spill; the Chernobyl, Fukushima, and Three Mile island nuclear accidents; and the Love Canal incident. The modern approaches of metabonomics/metabolomics are highlighted, with the resurrected importance of gut microflora and the human microbiome project being mentioned. The individual chapter titles are given below:
2
/ISSX Newsletter / Issue 2, 2015
Measuring Toxicity and Assessing Risk; Toxicokinetics; Biotransformation; Cellular Sites of Action; Genomics and New Genetics in Toxicology; Carcinogenesis; Reproductive Toxicology and Teratology; Respiratory Toxicology; Cardiovascular Toxicology; Neurotoxicology; Hepatic Toxicology; Renal Toxicology; Immunotoxicology; Ecological Toxicology; Applications: Pharmacology and
Toxicology; Applications: Forensic Toxicology; Applications: Environmental Toxicology and Pollution; Applications: Radiation; Applications: Food Safety; Applications: Toxins. Each chapter is followed by a bibliography that provides straightforward access to more detailed literature. Extensive cross referencing makes it easier to integrate and understand the presented material, especially if approaching it for the first time. An index of 25 pages in length is provided containing over 2,000 entries, a valuable must for such a comprehensive text. This book has been expanded since its first edition in 1996 (272 pages), through a second in 2006 (392 pages), to its present incarnation. The authors have enhanced this text by revising and updating it to include modern ideas and modes of practice, especially the, “rapid expansion of toxicogenomics.” The wording on the back cover states, “The easy-to-follow format and clear presentation of information in this book will make this one of the most useful references on your shelf” and I would not disagree.
Reviewed by:
Steve Mitchell Faculty of Medicine Imperial College London London SW7 2AZ, UK
Book Ordering Information:
CRC Press Taylor and Francis Group 6000 Broken Sound Parkway NW Suite 300 Boca Raton, FL USA 33487-2742 http://www.crcpress.com http://www.taylorandfrancis.com
7th International Symposium on Drug Metabolism and Pharmacokinetics Consistent with the Society’s objectives of increasing internationalization and expanding scientific outreach, ISSX sponsored the 7th Symposium on Drug Metabolism and Pharmacokinetics, February 19–21, at the National Institute of Pharmaceutical Education and Research (NIPER) in Chadigarh, India.
ISSX President-Elect Geoff Tucker and Council member Ann Daly were invited to present lectures at the symposium.
/ISSX Newsletter / 3
Symposium attendees pose for a picture at NIPER in Chadigarh, India.
Issue 2, 2015
The director of NIPER, Professor K.K. Bhutani, and Geoff Tucker light the ceremonial lamp inaugurating the symposium.
ISSX Welcomes New 2015 Members! Marko Andric, SOLVO Biotechnology, United States
Karsten Holm, Alliance Pharma, Inc., United States
Jyotsna Bahl, Tata Consultancy Services, Ltd., India
Yanjun Hong, National University of Singapore, Singapore
Thomas Ballard, Jr., Pfizer, Inc., United States
Carol Huang, EastWest Recruiting, United States
Rabi Bhatta, CSIR-Central Drug Research Institute, India
Mitsuru Inamura, ReproCELL, Japan
Jessica Bonzo, Thermo Fisher Scientific, United States Barbara Borowa-Mazgaj, Poland Marija Bosilkovska Richard Burton, Q2 Solutions, United States Alexandre Catoire, Novartis, United States Pei-Yu Chen, Public Health Research Institute, United States Edna Choo, Genentech, Inc., United States Richard Cole, Quotient Bioresearch (Rushden) Ltd., United Kingdom Stephanie Dale, Genentech, Inc., United States
Barry Jones, Astrazeneca, United Kingdom Elizabeth Joshi, Merck Research Laboratories, United States
Pankajini Mallick, University of Houston, United States Niloufar Marsousi, Geneva University Hospitals, Switzerland Kazufumi Masuda, Shujitsu University, Japan Nigel McCracken, Debiopharm, Switzerland Leah McGurn, University of Saskatchewan, Canada
Yusuf Kachwala, SVKM's NMIMS, India
Zhuang Miao, Novartis Pharmaceuticals, United States
Michiharu Kageyama, The University of Manchester, United Kingdom
Jee Sun Min, Catholic University of Korea, Korea
Harpreet Kaur, New Gobind Public Welfare Society, India
Yoshiyuki Murakami, Astellas Pharma, Inc., Japan
Doyun Kim, The Catholic University of Korea, Korea
Tatiana Nanovskaya, UTMB, United States
Jiseon Kim, Korea
Michiko Niwa-Sakai, Asahikasei Pharma Corporation, Japan
Yuki Kishino, Daiichi Sankyo Co., Ltd., Japan
Anthony Dickie, Evotec, United Kingdom
Tetsu Kondo, Ono Pharmaceutical Co., Ltd., Japan
Anne Dumaine, Sanofi R&D, France
Valerie Kramlinger, Vanderbilt University, United States
Katie Plant, Cyprotex, United Kingdom
Majlinda Kullolli, Amgen, Inc., United States
Agnieszka Potega, Gdansk University of Technology, Poland
Chakradhar Lagishetty, University of Florida, United States
Orawin Prangsaengtong, Srinakharinwirot University, Thailand
Anja Ekdahl, DMPK RIA iMED AstraZeneca Molndal, Sweden
/ISSX Newsletter / Issue 2, 2015
Norihiko Iwazaki, Mitsubishi Tanabe Pharma Corporation, Japan
Bryan Mackowiak, University of Maryland - Baltimore, United States
Tiffany Dickerson, Amgen, Inc., United States
Sadaff Ejaz, XenoTech, United States
4
Daisuke Ishii, Teijin Pharma Limited, Japan
Miloslav Machá ek, Charles University in Prague, Czech Republic
Steven Erpelinck, TNO, The Netherlands Diána Feller, Humeltis, Ltd., Hungary
Hyun Lee, Korea Institute of Science and Technology, Korea
Samit Ganguly, St. Jude Children's Research Hospital, United States
Yat Hei Henry Leung, CRCHUM/UdeM, Canada
Eric Gonzalez
Michael Liao, University of Washington, United States
Alexia Grangeon, CRCHUM, University of Montréal, Canada
Gospel Nwikue, University of Liverpool, United Kingdom Jung Bae Park, Korea
Katharina Prestin, University of Basel, Switzerland Isabelle Ragueneau-Majlessi, University of Washington, United States
Kevin Lidberg
Amber Guidry, University of Alabama at Birmingham, United States
Jason Robarge, Indiana University School of Medicine, United States
Bo Lindmark, AstraZeneca R&D, Sweden
Suzzette Haney, Emulate, United States
Luc Rougee, Eli Lilly and Company, United States
Jennifer Lu
Ryosuke Shimizu, Shionogi & Co., Ltd., Japan
Asami Hayashi, Japan Tobacco, Inc., Japan
John Lynch, St. Jude Children's Research Hospital, United States
Kanumuri Siva Rama Raju, Central Drug Research Institute, India
Marci Smeltz, University of Florida, United States
Suresh Vatakuti, University of Groningen, Netherlands
Eric Solon, QPS, LLC, United States
Callee Walsh, Protea Biosciences, United States
Abhishek Srivastava, AstraZeneca, United Kingdom Junko Sugatani, University of Shizuoka, Japan Petter Svanberg, Sr., AstraZeneca R&D, Sweden
Francesca Wood, University of Manchester, United Kingdom
Meijuan Xu Yoshiya Yamamura, Otsuka Pharmaceutical Co., Ltd., Japan Fagen Zhang, The Dow Chemical Company, United States
Matthew Wright, Newcastle University, United Kingdom
ISSX Career Center Searching for experts in the field of drug metabolism, pharmacokinetics,pharmacodynamics, and other related areas? The ISSX Career Center job board is your premier resource to find skilled applicants. •C reate your Company Profile free of charge and explain the organization and work environment in detail. •W hen your positions are advertised on the ISSX Career Center, an e-mail advertising the
position is sent automatically to job seekers who have requested notifications about opportunities matching their search criteria. •B rowse résumés for free and pay only for the résumés that you select.
Post your jobs online today! When you use the ISSX Career Center, you ensure that your open positions are advertised in the right place.
Visit www.issx.org/careercenter, new and updated this year!
For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400. Copyright © 2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved. CORP-1060080-0090 12/14
/ISSX Newsletter / 5
For more than 150 years, a very special passion has driven the people of Merck. Our goal is to develop medicines, vaccines, and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to research and development. We’re just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we’ll meet that challenge. With all our heart.
Issue 2, 2015
Medical breakthroughs May coMe out of the lab. but they begin in the heart.
President’s Message Continued from page 1
is by election, members of other ISSX committees are appointed by the incoming President. Have you ever considered volunteering your time and skills to ISSX? Serving on an ISSX committee is an invaluable way of contributing to the ongoing success of the Society. Should you wish to do so, please register your interest by visiting www.issx.org/volunteer. John Miners ISSX President
ISSX MEMBER SPOTLIGHT What do you think the future of xenobiotic research will look like? What excites you about your research? What advice can you offer to students and young investigators? Answer these questions and you could be featured in our next newsletter. Complete the form online: www.issx.org/Membership/Spotlight.
BE PART OF THE PROGRAM Submit an Abstract to the 20th North American ISSX Meeting by August 14 A highlight of every ISSX meeting is the showcase of investigators presenting cutting-edge research on the latest advances in topics related to drug metabolism and pharmacokinetics during abstract poster sessions. Investigators have the opportunity to share important findings with colleagues and interact with global leaders in the field. Benefits of presenting a poster at the 20th North American ISSX Meeting include:
6
/ISSX Newsletter / Issue 2, 2015
•P ublication—Accepted abstracts of original work are published in a top-ranked journal, Drug Metabolism Reviews (with a 5-year Impact Factor of 6.218). •V isibility and Feedback—Global experts in the field of Xenobiotic research will see your work and dedicated viewing times create opportunities for one-on-one discussion with faculty and attendees. Presenters benefit from this interaction by gaining feedback on current and future projects, while also discovering the latest research results and advances in DMPK. •A cknowledgement of Exceptional Research—Investigators meeting certain criteria are eligible to participate in the Poster Awards Competition. Encompassing a category for graduate students and another for postdocs, this competition is available for poster authors to compete for cash prizes and awards. • I nternational Recognition—The winners of the Poster Awards Competition as well as all authors presenting posters at the meeting will present their research on the international stage and may include their presentation on their CV. Visit www.issx.org/20na/abstracts to present your work at the last ISSX meeting of the year!
20th North American ISSX Meeting Hilton Bonnet Creek Hotel | Orlando Florida, USA October 18–22, 2015
Meeting Organizing Committee Chairs
SCIENTIFIC PROGRAM
Hartmut Derendorf (CoChair), University of Florida, Gainesville, Florida, USA
Sunday, October 18, 2015
Stephan Schmidt (CoChair), University of Florida, Orlando, Florida, USA
Meeting Organizing Committee Members Vikram Arya, U.S. Food and Drug Administration, Columbia, Maryland, USA Reggie Frye, University of Florida, Gainesville, Florida, USA Margaret James, University of Florida, Gainesville, Florida, USA R. Scott Obach, Pfizer Inc., Groton, Connecticut, USA
Amin Rostami, University of Manchester, Manchester, UK
Geoff Tucker, Simcyp Ltd., Sheffield, UK
Short Course 2: Introduction to Pharmacometric and Regulatory Aspects Pertaining Special Populations Chair: Jeff Barrett, Sanofi, Bridgewater, New Jersey, USA Short Course 3: Methodological Aspects of Transporter Measurements Chair: Per Artursson, Uppsala University, Uppsala, Sweden Short Course 4: Introduction to PK/PD of Proteins, Antibodies and Protein Conjugates Chair: Bernd Meibohm, University of Tennessee Health Science Center, Memphis, Tennessee, USA
Monday, October 19, 2015 Plenary Session 1: Sources of Variability in PK and PD Chair: Amin Rostami, University of Manchester, Manchester, UK Parallel Symposium 1: New Developments in Transporters Co-Chairs: Andrew Parkinson, XPD Consulting, Shawnee Mission, Kansas, USA and Jashvant Unadkat, University of Washington, Seattle, Washington, USA Parallel Symposium 2: Preclinical Applications of Systems Pharmacology in Drug Development Chair: Mirjam Trame, University of Florida, Orlando, Florida, USA Oral Presentations of Selected Abstracts from New Investigators The New Investigators Forum: Career and Leadership Development Co-Chairs: Tom Baillie, University of Washington, Seattle, Washington, USA and Andrew Parkinson, XPD Consulting, Shawnee Mission, Kansas, USA
/ISSX Newsletter / 7
Mirjam Trame, University of Florida, Orlando, Florida, USA
Short Course 1: Maximizing the Predictability of PBPK Models Using Top-down Approach Chair: Ping Zhao, FDA, Silver Spring, Maryland, USA
OPENING KEYNOTE LECTURE: Personalized Medicine—Myth or Reality Larry Lesko, Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, Florida, USA
Issue 2, 2015
Andrew Parkinson, XPD Consulting, Shawnee Mission, Kansas, USA
Program subject to change.
Wednesday, October 21, 2015 Plenary Lecture 2: Understanding Idiosyncratic Hepatoxicity: From Cage to Clinic Paul Watkins, University of North Carolina, Chapel Hill, North Carolina, USA Tuesday, October 20, 2015 Plenary Lecture 1: Significance of Uptake and Efflux Transporters in the Liver Yuichi Sugiyama, RIKEN, Tokyo, Japan Parallel Symposium 3: Adverse Outcome Pathways: From Research to Regulation Chair: Charlene McQueen, US Environmental Protection Agency, Research Triangle Park, North Carolina, USA Parallel Symposium 4: Retrometabolic Drug Design Chair: Erik Bodor, Bodor Labs, Miami, Florida, USA
Parallel Symposium 5: Transporters and Biomarkers in Kidney and Liver: Implications for Drug Development Co-Chairs: Vikram Arya, FDA, Columbia, Maryland, USA and Lei Zhang, FDA, Silver Spring, Maryland, USA Parallel Symposium 6: Preclinical Applied Pharmacometrics in Drug Development Chair: Stephan Schmidt, University of Florida, Orlando, Florida, USA Plenary Session 2: Regulatory Requirements for Drug-Drug Interaction Studies—A Comparison around the World Chair: Hartmut Derendorf, University of Florida, Gainesville, Florida, USA
Parallel Symposium 7: Phase II Metabolism and Relevance for Drug Safety Chair: Michael Zientek, Pfizer, San Diego, California, USA Parallel Symposium 8: Pharmaceuticals and Personal Care Products in the Environment Chair: Margaret James, University of Florida, Gainesville, Florida, USA Thursday, October 22, 2015 Plenary Lecture 3: Preclinical Development of Biologics Douglas Leipold, Genentech, South San Francisco, California, USA Parallel Symposium 9: Determining CYP Activity in vivo—A Challenge for the Implementation of Personalized Drug Dosage Chair: Geoff Tucker, University of Sheffield, Sheffield, United Kingdom Parallel Symposium 10: Lab on a Chip Chair: Edward Kelly, University of Washington, Seattle, Washington, USA
ISSX NEW INVESTIGATORS FORUM
8
/ISSX Newsletter / Issue 2, 2015
New investigators are invited to attend a special session on Monday, October 19 from 7:00 p.m. – 9:00 p.m. The goal of this forum is to provide new investigators with an insight into career opportunities in different segments of the pharmaceutical sciences (academia, “big pharma,” biotech, and government), with an emphasis on both making oneself more “marketable” to potential employers and acquiring critical leadership skills for a successful career. Topics that will be addressed include
employers’ expectations at the time of hiring, and what are the necessary skill sets for career advancement and leadership development. The forum will take the form of a panel discussion with senior scientists representing each of the above career paths, followed by a Q&A session. This event will be of particular interest to graduate students, postdoctoral fellows, and investigators in the early stages of their careers.
NOMINATE A COLLEAGUE BY AUGUST 17 Nominations are currently being accepted for two prestigious awards that will be presented at this meeting: The North American Scientific Achievement Award is named in honor of Ronald W. Estabrook and is sponsored by XenoTech. This award is presented to an ISSX member to recognize meritorious contributions by mid-career scientists who have had a major impact on research in the field in the North American Region. The North American New Investigator Award is named in honor of James R. Gillette. It is presented to an ISSX member or nonmember who has made significant contributions to the field within the North American Region. Visit www.issx.org/awards for more details and to submit a nomination by August 17.
REGISTRATION
Register to attend at www.issx.org/20na/registration. Register before Friday, July 31 to receive the early registration discount. Members receive discounted registration!
VENUE/HOTEL INFORMATION
Hotel rooms have been blocked at the Hilton Orlando Bonnet Creek, adjacent to Walt Disney World, at a special meeting rate of $215 for single/double, exclusive of taxes. Reserve your accommodations now. The deadline for rooms in the ISSX block is Monday, September 21, 2015. For reservations, visit www.issx.org/20na/hotel; or telephone the hotel at +1 (888) 353-2013. Be sure to identify yourself as an ISSX meeting attendee in order to secure our special rate.
MAKE IT A VACATION! Make plans to enjoy Florida’s world famous theme parks and many other attractions in Orlando with your family, friends, and fellow meeting attendees. The meeting organizers have programmed in a free afternoon on Tuesday, October 20 to provide attendees the opportunity for hours of fun at their choice of attractions. The hotel’s complimentary shuttle picks up at the hotel and
takes ISSX meeting attendees directly to Walt Disney World® Theme Parks and back. Specially reduced priced tickets to several Orlando area attractions are available to ISSX meeting attendees. Visit www. issx.org/20na/attractions for more information.
UPCOMING Meetings
21st North American ISSX Meeting Rhode Island Convention Center Providence, Rhode Island September 24–28, 2017 Meeting Chair: Jashvant Unadkat, Ph.D.
/ISSX Newsletter / 9
11th International ISSX Meeting Busan Exhibition and Convention Center Busan, Korea June 12–16, 2016 Meeting Chair: Jae-Gook Shin, Ph.D.
14th European ISSX Meeting Güzenich Köln Cologne, Germany June 26–29, 2017 Meeting Chair: Uwe Fuhr, Ph.D.
Issue 2, 2015
20th North American ISSX Meeting Hilton Orlando Bonnet Creek Orlando, Florida, USA October 18–22, 2015 Meeting Chairs: Hartmut Derendorf, Ph.D. & Stephan Schmidt, Ph.D.
13th European ISSX Meeting in Review Four hundred scientists, students, and exhibitors convened at the newly-constructed Technology and Innovation Centre of the University of Strathclyde in Glasgow, Scotland for the 13th European Meeting of the International Society for the Study of Xenobiotics. The meeting was co-chaired by Roland Wolf of the University of Dundee, Dundee, United Kingdom and Ann Daly of Newcastle University, Newcastle Upon Tyne, United Kingdom. These co-chairs and the
Meeting Organizing Committee developed an outstanding program addressing an array of topical areas in the science of xenobiotics. Attendees represented 32 countries. While seventy percent of attendees were from the European region, ISSX also welcomed scientists from other countries including Canada, China, India, Japan, Thailand, Singapore, and the United States.
View the Meeting Photos at ISSX.SMUGMUG.COM
10
/ISSX Newsletter / Issue 2, 2015
The meeting was preceded by four short courses attended by 80 meeting registrants. The courses featured topics ranging from Mass Spectrometry in Drug Metabolism Studies, Stem Cell Derived Tissues in Toxicology, Physiologically-based Pharmacokinetic Modelling, and New Horizons in Mass Spectrometry.
attendees could network with each other and spend time with the 24 companies exhibiting their products and services at the meeting.
The meeting program commenced with an opening keynote on Protein Kinase Inhibitors: Major Drugs of the 21st Century presented by Professor Sir Philip Cohen of the University of Dundee, Dundee, United Kingdom. The keynote was followed by a welcome reception where
The meeting also featured the presentation of the prestigious ISSX European Awards. The 2015 ISSX European Scientific Achievement Award was presented to James Brian Houston, Ph.D. The New Investigator Award, in honor of Karl J. Netter was presented by Dr. Netter to Daniel J. Antoine, Ph.D. Both awardees were presented with an honorarium and plaque and each presented a lecture to the award session attendees.
ISSX European award winners Dr. Daniel J. Antoine (left) and Dr. James Brian Houston (right).
Dr. Karl Netter presents the New Investigator Award to Dr. Daniel J. Antoine. Continued on next page
The scientific program included lectures on a variety of relevant topics delivered in plenary sessions and parallel symposia. Many of the parallel symposia featured presentations from abstract authors who were selected from the 179 poster abstracts and invited to present by the sessions’ co-chairs. On Tuesday, June 23, the Lord Provost of Glasgow City hosted a reception for ISSX attendees at the historic Glasgow City Chambers. Later that evening, ISSX hosted a New Investigators Reception for nearly 40 scientists who
The Society is grateful to the Meeting Co-Chairs and Meeting Organizing Committee along with all of the session chairs and speakers. The poster presenters,
have been in their field for ten years or less at the unique Glaswegian restaurant Waxy O’Connor’s. The following evening, more than one hundred attendees met at the Old Fruitmarket of Glasgow for the meeting’s premier social event. After cocktail hour, a bagpiper led attendees to their seats. A five-person band entertained everyone with native Scottish songs throughout dinner and afterwards instructed attendees in a ceilidh, a series of traditional dances.
attendees, and exhibiting companies were an essential component of this meeting and their participation and support is greatly appreciated.
/ISSX Newsletter / 11
Continued on next page
Issue 2, 2015
Attendees enjoy the Meeting Dinner and Ceilidh at the Old Fruitmarket.
13th European ISSX Meeting Poster Award Winners (From Left to Right): Hugues de Boussac, Ayse Ufuk, Frauke Assmus, Michiel den Braver, Ming Li, and Marc-Olivier Boily.
The meeting concluded with the presentation of poster awards by Poster Awards Review Committee member Eddie Morgan and Meeting Co-Chairs Roland Wolf and Ann Daly, to graduate/predoctoral and postdoctoral attendees for best poster presentation in those categories. The award recipients were:
Postdoctoral First Place: In Silico Prediction of Hepatocellular Drug Binding; Frauke Assmus; Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, University of Manchester; Manchester, United Kingdom
Graduate/Predoctoral First Place: Involvement of Different Cytochrome P450 Isoforms in the Sequential 2-Step Bioactivation of Diclofenac and the Physiological Relevance of Subsequent Detoxification by Glutathione S-Transferases; Michiel W. den Braver; VU University Amsterdam; Amsterdam, The Netherlands
12
/ISSX Newsletter / Issue 2, 2015
Second Place: Precision-Cut Intestinal Slices as Ex Vivo Model to Study the Uptake of Bile Acids by ASBT in the Intestine; Ming Li; Department of Pharmacy, University of Groningen; Groningen, The Netherlands Third Place: Is the Use of 1-Aminobenzotriazole as Cytochrome P450 Inactivator in Rat Studies Appropriate?; Marc-Olivier Boily; Centre de Recherche, Hôpital Maisonneuve-Rosemont, Faculté de Médecine, Université de Montréal; Montreal, Quebec, Canada
Second Place: Comparison of Respiratory Drug Accumulation and Lysosomal Sequestration in NR8383 and Primary Human Alveolar Macrophages; Ayse Ufuk; Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, University of Manchester; Manchester, United Kingdom Third Place: CAR Transcriptional Activity is Under the Influence of EGF in Primary Human Hepatocytes; Identification of CAR Specific Target Genes; Hugues de Boussac; INSERM U1183, IRMB, Hôpital Saint-Eloi; Montpellier, France
ISSX Newsletter is published quarterly in the spring, summer, autumn, and winter. For information concerning advertising in this publication, including rates and specifications, please visit www.issx.org or contact information@issx.org. Advertise with ISSX in the quarterly ISSX Newsletter. Rates and additional advertising opportunities are available at www.issx.org/advertising2015.
Change of Address
If your mailing address, telephone, fax number, or e-mail has changed or will change, please let us know as soon as possible. You may update your contact information at any time using the online membership directory, which you can access in the Member Only section of the Web site. If you have forgotten your username and/or password, please contact information@issx.org.
Deadline for the submission of material to the ISSX Office: ISSUE
MATERIALS DEADLINE*
RELEASE DATE
Issue 3
August 14, 2015
September 2015
Issue 4
November 13, 2015
December 2015
*
Subject to change
Editor Dr. Allen Cato, III Cato Research, LTD 6480 Weathers Place, Suite 104 San Diego, California 92121 USA Telephone: +1-858-452-7271 Fax: +1-858-452-7784 E-mail: jcato@cato.com
Advertise with ISSX The quarterly ISSX Newsletter is an online publication featuring Society updates, scientific articles of interest, book reviews, summaries of ISSX meeting proceedings, and more. This publication is designed to update the ISSX membership on the activities and events of the organization and to provide an information forum. Not only is the ISSX Newsletter promoted directly to all ISSX Members, but, as of 2012, it is also available to anyone who visits the ISSX website. Visit www.issx.org/advertising2015 today!